Tatva Chintan Pharma Chem valuation

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
Price multiples — at each FY-end close
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
58.22×————
4.50×————
5.64×————
Enterprise multiples
5.81×————
29.80×————
43.66×————
Yield
1.7%————
−2.2%————
Reference — adjusted share basis
₹1,565.90————
₹26.90₹17.98₹2.44₹12.98₹19.45
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

TATVA₹1,565.90

Tatva Chintan Pharma Chem Limited

· Chemicals
₹ CrorePeersVISHNUJUBLCPLKIRIINDUSFOSECOINDCHEMPLASTSDDEVPLSTIKGUJALKALIYASHOMcap ₹3,663 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
Multiples — ₹ Crore base
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Price Multiples — at each FY-end close
P/E————58.22
P/B————4.50
P/Sales————5.64
Enterprise Multiples
EV/Sales————5.81
EV/EBITDA————29.80
EV/EBIT————43.66
Yield
Earnings Yield %————1.72
FCF Yield %————-2.25
Reference — adjusted share basis
Price (FY-end close, adj.)————1,565.90
EPS (adj.)19.4512.982.4417.9826.90
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.